Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months
渤健公司高管表示,如果FDA對Leqembi皮下注射劑進行加速審批,可能在提交後8個月內獲得批准,而不是12個月。
Biogen Exec Says if FDA's Review for Subcutaneous Leqembi Is Expedited Approval Could Come After 8 Months From Submission Vs 12 Months
渤健公司高管表示,如果FDA對Leqembi皮下注射劑進行加速審批,可能在提交後8個月內獲得批准,而不是12個月。
譯文內容由第三人軟體翻譯。